212 Users Online
Pulmonary Arterial Hypertension Market Segmentation by Drug Class - Endothelin Receptor Antagonists | PDE-5 Inhibitors | Prostacyclin and Prostacyclin Analogs | SGC Stimulators
Newly-released Pulmonary Arterial Hypertension Market analysis report by Persistence Market Research shows that global sales of Pulmonary Arterial Hypertension Market in 2021 was held at US$ 7.1 Bn. With 6.2% growth during 2022 – 2032, the market is projected to reach a valuation of US$ 13.7 Bn by 2032. Prostacyclin and Prostacyclin Analogs is expected to be the highest revenue-generating segment, accounting for an expected CAGR rate of 6.3% during 2022 – 2032.
|
Attribute |
Details |
|
Global Pulmonary Arterial Hypertension Market (2022) |
US$ 7.5 Bn |
|
Global Pulmonary Arterial Hypertension Market (2032) |
US$ 13.7 Bn |
|
Global Pulmonary Arterial Hypertension Market CAGR (2022 – 2032) |
6.2% |
|
North America Pulmonary Arterial Hypertension Market (2022) |
US$ 3.1 Bn |
|
U.S. Pulmonary Arterial Hypertension Market (2022) |
US$ 2.8 Bn |
|
Key Companies Profiled |
|
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
As per the Pulmonary Arterial Hypertension Market research by Persistence Market Research - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value increased at around 5.4% CAGR.
Pulmonary Arterial Hypertension (PAH) is a rare lung condition that often influences young people. The enormous number of kids with untreated PAH presents critical market development prospects and is supposed to energize the utilization of pulmonary arterial hypertension medications. As per the American Lung Association, around 500 to 1,000 new PAH patients are diagnosed in the United States every year.
Notwithstanding, the medicines' unfriendly impacts might adversely affect the market's development. Vasodilators are usually furnished to individuals with PAH to unblock impeded or confined blood veins. Vasodilators produce an array of adverse results, including tachycardia, edema, heart palpitations, and chest torment, and that is only the tip of the iceberg, as indicated by studies. Moreover, PAH drugs used to treat hypertension and enlarge blood supply routes should give sensible proof of their security and adequacy. Before these drugs are marketed, these drugs need to be approved by the FDA.
Amid COVID-19, due to the rising number of hospitalized PAH-COVID-19 patients, the pandemic augmented the need for PAH drugs. Inferable from this, the market is projected to develop at a CAGR of 6.2% over the approaching 10 years.
Pulmonary Arterial Hypertension Market was valued at US$ 7.1 Bn in 2021. According to Persistence Market Research, Pulmonary Arterial Hypertension Market revenue would increase 1.8X times between 2022 and 2032, reaching roughly US$ 13.7 Bn in 2032.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionIn emerging nations, the increasing geriatric population positively affects the pulmonary arterial hypertension market. As per a United Nations projection, the world's maturing populace would number approximately 727 million individuals matured 65 and more in 2020. This number is supposed to be twofold in the following twenty years, coming to 1.5 billion by 2050.
As indicated by the United Nations Population Fund and HelpAge India, India's old populace would reach 173 million by 2026. Because of the significant extent of the populace that is maturing, the pervasiveness of PAH in the more seasoned populace is expected to ascend soon. One of the non-modifiable variables that increase the risk of PAH is growing age. Besides, because of diastolic brokenness and age-related blood vessel solidifying, the older population base is powerless to this infirmity, which adds to the business need.
Which Region is projected to Offer the Largest Opportunity for Pulmonary Arterial Hypertension Market?
North America dominated the Pulmonary Arterial Hypertension market and held the largest revenue share. The complex healthcare framework in the United States elevates access to advanced treatments, which represents a considerable share. Increased awareness, a high pace of diagnosis, and strong government estimates all add to the market's development around here.
The presence of significant contenders and a well-planned repayment structure likewise help to the regional market's development. The region’s demand for developed medical services related to Pulmonary Arterial Hypertension is being driven by the expanded pervasiveness of chronic and infectious illnesses, as well as a high diagnosis rate.
Sales Team
Client Partner
U.S. Market Analysis
The United States is expected to account for the highest market share of US$ 5.3 Bn by the end of 2032. In U.S. PAH is a rare condition in which around 500 – 1,000 new cases are diagnosed every year. The use of Pulmonary Arterial Hypertension in the U.S. has extended its applications to many fields, such as vaccine administration, hormonal delivery, cancer therapy, and pain management, which boosts growth for the market in the United States.
U.K. Market Analysis
The spontaneous or idiopathic form of pulmonary arterial hypertension affects around 6,500 people in the UK. Owing to this, the market in the country is projected to reach a valuation of US$ 529.2 Mn by 2032, growing at a CAGR of 6.9% during 2022 – 2032.
Japan Market Analysis
In Japan, the prevalence of PAH was estimated at 3.2 per 100,000, and the incidence at 70-100 cases every year. However, the investment towards the non-occurrence of PAH led the market value in Japan at US$ 343 Mn in 2021.
South Korea Market Analysis
Between 2008 and 2016, over 1,307 patients were newly diagnosed with PAH which suggests an annual incidence of 4.84 patients per million people per year. The statistics a stable market for South Korea with US$ 145 Mn in 2021.
Growing demand for endothelin receptor antagonists is expected to boost the growth of the market. Check How?
As a result of the expanded demand for endothelin receptor antagonist prescriptions, the endothelin receptor antagonist segment is expected to increase at 6.3% during 2022 – 2032. They are frequently recommended as a designated treatment for switching heart and lung damage, slowing PAH progression, and dilation of blood vessels, in addition to other factors.
Clinical investigations have shown that individuals with pulmonary arterial hypertension create a ton of endothelin, which causes hypertension. Thus, doctors frequently prescribe an endothelin receptor antagonist to restrict the amount of endothelin in the blood vessels. Moreover, expanding interest in endothelin receptor antagonist research and development will assist the segment with further growth. There has been a surge in research focusing on the endothelin receptor, which has other therapeutic advantages, especially in the treatment of pulmonary arterial hypertension.
What are the insights about Prostacyclin and Prostacyclin Analogs?
Prostacyclin and Prostacyclin Analogs segment is expected to account for the highest CAGR rate of 5.7% during 2022 – 2032. New cases are expected to happen in one to two individuals for every million in the United States every year, as per the National Organization for Rare Disorders. In Europe, the rate is expected to be comparative. Pneumonic hypertension influences individuals, all things considered, and it turns out to be normal as they progress in years. The fast increment is due to the change in way of life, which incorporates an absence of actual activity and expanded utilization of liquor and tobacco, the two of which raise the risk of hypertension and high blood pressure.
Market through Oral Route of Administration Accounts for the Highest Revenue. Check Why?
Oral Route of Administration accounted for around 60% share in the pulmonary arterial hypertension market in 2021. Oral PAH meds incorporate Letairis, Opsumit, Adcirca, and Revatio. The key factors supporting the adoption of oral drug administration incorporate patient security, high viability, and speedy medication delivery.
United Therapeutics, Johnson & Johnson, Gilead Sciences, Viatris, and Bayer are among the few businesses that account for a significant share in the pulmonary arterial hypertension market, owing to their patents. However, as patents expire, more pharmaceutical companies are expected to enter the PAH market. Market players are involved in deploying various strategic initiatives to increase their market share. This includes product R&D and launches, distribution network expansion, partnerships, and mergers and acquisitions.
Some of the recent developments of key Pulmonary Arterial Hypertension providers are as follows:
Similarly, recent developments related to companies offering Pulmonary Arterial Hypertension have been tracked by the team at Persistence Market Research, which are available in the full report.
By Drug Class
By Type
By Route of Administration
By Region
The global Pulmonary Arterial Hypertension Market is worth more than US$ 7.1 Bn at present.
The value of the Pulmonary Arterial Hypertension Market is projected to increase at a CAGR of around 6.2% during 2022 – 2032.
The value of the Pulmonary Arterial Hypertension Market increased at a CAGR of around 5.4% during 2017 – 2021.
Growing initiatives by key market players, high prevalence of pulmonary arterial hypertension, adoption rate, and entry of generics are some of the key drivers of this market are some of the key factors shaping the Pulmonary Arterial Hypertension market.
The market for Pulmonary Arterial Hypertension Market in China is projected to expand at a CAGR of around 7.3% during 2022 – 2032.
While the market in South Korea is expected to grow at nearly 6.4%, the market in Japan is projected to register a CAGR of nearly 5.5% during 2022 - 2032.
